4-TERT-BUTYLPYROCATECHOL

WHAT IS 4-TERT-BUTYLPYROCATECHOL?

4-tert-Butylpyrocatechol, also known as 4-tert-butylbenzene-1,2-diol, 4-tert-butylcatechol and TBC, is a catechol derivative with a tert-butyl group attached at position four of the aromatic ring. Catechol is the common name for benzene-1,2-diol, so the molecule retains two adjacent phenolic hydroxyl groups. The industrial abbreviation TBC usually refers to this defined inhibitor when used in monomer-stabilization discussions.

The exact chemical name and CAS number remain important because other tert-butyl phenols and catechol-related materials have different properties. An inhibitor is selected to delay or suppress unwanted polymerization under specified conditions. Its function differs from that of a processing catalyst, a cure accelerator, or an antioxidant chosen primarily to protect a finished polymer during service.

Commercial monomer supply often involves an intentionally controlled inhibitor concentration. 4-tert-butylcatechol is useful because reactive monomers need to remain suitable for later polymerization rather than polymerize unpredictably during handling. The inhibitor's presence also affects downstream processing.

A polymer producer may need to account for the supplied TBC level when evaluating induction time or initiator demand, without removing protection prematurely from stored monomer. The central application question is therefore not whether inhibition is good or bad. It is whether the inhibitor system provides appropriate protection during handling while remaining compatible with the planned, controlled conversion into a polymer.

Common Product and Chemical Names

- 4-tert-Butylpyrocatechol
- 4-tert-Butylcatechol
- p-tert-Butylcatechol
- Para-tert-butylcatechol
- p-tert-Butylpyrocatechol
- 4-Tertiary-butylcatechol
- 4-tert-Butylbenzene-1,2-diol
- 4-(1,1-Dimethylethyl)benzene-1,2-diol
- 1,2-Benzenediol, 4-(1,1-dimethylethyl)-
- TBC
- 4-TBC
- PTBC, commercial shorthand requiring chemical context

4-tert-Butylpyrocatechol is also known as 4-tert-butylcatechol, a useful alternate name in technical prose because it identifies the same substituted diphenol without ambiguity; registry records also describe it as 1,2-Benzenediol, 4-(1,1-dimethylethyl)-. Para-tert-butylcatechol and TBC are also common in supplier and monomer-handling documents. The abbreviations 4-TBC and PTBC should identify the same CAS 98-29-3 material before being used in purchasing or dosing records.

Catechol, hydroquinone, MEHQ, BHT, and tert-butylhydroquinone are different substances. Shared phenolic chemistry does not make them synonyms or establish equivalent inhibitor performance in a particular monomer system.

CAS NO, EC / EINECS NO AND INCI NAME

- Product title: 4-tert-Butylpyrocatechol
- CAS number: 98-29-3
- EC/EINECS number: 202-653-9
- Common technical name: 4-tert-Butylcatechol
- Structural description: 4-tert-Butylbenzene-1,2-diol
- Common abbreviation: TBC
- Molecular formula: C10H14O2
- Molecular weight: Approximately 166.22 g/mol
- Chemical family: Substituted aromatic diphenol
- Hydroxyl groups: Two adjacent phenolic groups
- INCI information: No verified cosmetic INCI designation is assigned here
- Primary commercial role: Industrial polymerization inhibitor
- Mixture identity: Commercial solutions include carriers requiring separate composition disclosure

4-tert-Butylpyrocatechol chemical identifiers establish the active ingredient rather than a complete inhibitor product specification. A solid grade, a methanol-containing concentrate, and an aqueous commercial concentrate require different composition and handling information even when their active ingredient is TBC. An industrial inhibitor should not be presented as a cosmetic skin-lightening or general personal care ingredient. Its occupational hazards and application evidence need to be understood in the industrial context for which it is selected.

PHYSICAL AND CHEMICAL PROPERTIES

- Physical form of the neat ingredient: Crystalline solid
- Commercial solid forms: Powder, crystals, or flakes
- Typical appearance: White to creamy or pale material; grade-dependent
- Commercial solution appearance: Often clear amber; carrier and grade-dependent
- Molecular formula: C10H14O2
- Molecular weight: Approximately 166.22 g/mol
- Melting behavior: Representative reported ranges approximately 52-58 degrees Celsius
- Normal boiling point: Representative literature value approximately 285 degrees Celsius
- Volatility relative to reactive light monomers: Low; phase distribution must be assessed
- Solubility in methanol: Demonstrated in representative reagent information; actual concentration and temperature matter
- Water compatibility: Depends on concentration and commercial formulation; a named aqueous concentrate does not define dilute-solution solubility
- Functional groups: Two phenolic hydroxyl groups
- Oxidation chemistry: Can form quinone-related products under suitable conditions
- Radical-related function: Industrial inhibition in compatible systems
- pH of neat solid: Not a standalone aqueous pH property
- Assay, moisture, color, and insoluble matter: Grade-specific parameters
- Representative solid-product closed-cup flash point: Approximately 113 degrees Celsius in supplier information; not a processing recommendation
- Relevant hazards: Harmful by ingestion or skin contact, corrosive, skin sensitizing in representative supplier classifications

4-tert-Butylpyrocatechol reference physical values are useful for identification and planning, but they are not universal release limits. Melting range, carrier composition, and analytical methods should be taken from the exact offered grade before production decisions are made. Commercial concentrate behavior cannot be predicted by reading only the neat compound's properties.

A solution's viscosity, flash point, crystallization tendency, and compatibility are properties of the complete mixture. The two hydroxyl groups of 4-tertiary-butylcatechol are phenolic rather than ordinary aliphatic alcohol groups. Their acid-base and oxidation behavior need to be considered through the actual chemistry rather than assigned the same reactivity as a glycol. A high boiling point explains why TBC tends to remain in certain liquid or residue locations during separation. It does not establish protection throughout a distillation system or justify heating without a process-specific assessment.

MOLECULAR STRUCTURE AND INHIBITION CHEMISTRY

4-tert-Butylpyrocatechol has adjacent hydroxyl groups that support electron and hydrogen-transfer pathways associated with catechol chemistry. The aromatic framework can stabilize certain radical-related intermediates, making the compound useful in selected inhibition systems. In p-tert-butylpyrocatechol, the tert-butyl substituent changes the molecule's hydrophobic character and its interactions compared with unsubstituted catechol.

This can influence compatibility in organic monomers and the overall behavior of the inhibitor. Inhibition involves a network of reactions rather than one universal event in every substrate. Radical generation, oxygen availability, inhibitor consumption, contaminants, and temperature determine whether the selected chemistry remains effective.

Oxidation can generate quinone-related species and contribute to changes in appearance. A darker solution may therefore require investigation, but color alone cannot quantify the remaining active inhibitor or establish a storage decision. The molecule does not eliminate all sources of polymerization risk.

Thermal conditions, peroxides, incompatible contamination, and inadequate distribution can overwhelm a system even when the inhibitor was initially present. A useful technical description distinguishes chemical mechanism from operational protection. Knowing that TBC intercepts radical-related pathways is a reason to select and test it, while protection requires the complete validated monomer-handling system.

INHIBITOR, RETARDER, AND ANTIOXIDANT: PRACTICAL DISTINCTIONS

4-tert-Butylpyrocatechol functions as an inhibitor that can provide an induction period during which polymer formation is suppressed under defined conditions. A retarder may reduce polymerization rate without providing the same clear delay, although real behavior depends on the specific chemistry and test method. p-tert-Butylcatechol is commonly selected as a monomer inhibitor rather than as a generic cure-control additive for every finished formulation.

4-tert-butylcatechol's effect in a resin mixture needs direct evaluation because initiators, accelerators, and additional ingredients change the reaction environment. Antioxidant chemistry overlaps with aspects of radical inhibition, but the application objective differs. Protecting stored monomer from unwanted conversion is not equivalent to protecting a cured rubber article from long-term oxidative aging.

An inhibitor's depletion can be a normal result of its function. That does not make a depleted system acceptable; it means the protection strategy needs monitoring and a defined response before the approved operating margin is lost. The distinction also affects purchasing. An antioxidant recommended for a polymer compound cannot be assumed to replace the inhibitor specified by a monomer supplier merely because both are phenolic chemicals. Comparisons should therefore use application-specific tests and endpoints. A generic radical-scavenging result in a laboratory solvent does not establish equal performance in a bulk monomer storage tank.

OXYGEN AND STYRENE INHIBITION

4-tert-Butylpyrocatechol (TBC) stabilizes styrene in an inhibition system that depends on an appropriate oxygen environment. The relevant inhibitor chemistry is not supported simply by measuring TBC concentration while ignoring dissolved oxygen and the system's operating conditions. This creates an important exception to a simplistic assumption that complete oxygen removal always improves storage.

An unreviewed change to oxygen-free blanketing can undermine a TBC-based styrene protection strategy. At the same time, oxygen management must account for flammability and equipment design. The requirement for oxygen-assisted inhibition is not an instruction to introduce oxygen casually, open a tank, or alter gas composition without engineering review.

Dissolved oxygen and headspace composition are related but not identical measurements. Mixing, transfer, temperature, and gas-liquid contact influence how the liquid acquires or loses oxygen. The approved operating strategy should come from the monomer supplier's current guidance and the site's process assessment.

Concentration, temperature, oxygen conditions, and monomer quality must be considered together rather than reduced to one numerical target. Other monomers require their own handling basis. Styrene's oxygen-dependent inhibition discussion should not be copied automatically into butadiene or another volatile, peroxide-sensitive material.

TEMPERATURE, DEPLETION, AND STORAGE DURATION

4-tert-Butylpyrocatechol can be consumed more rapidly as higher temperatures increase the rate of unwanted monomer reactions. A batch that was within specification at receipt may have a different protection margin after a period of warmer storage. The relationship is not captured by a universal shelf-life number.

Initial inhibitor content, oxygen conditions, monomer purity, storage history, and the actual temperature profile all influence the useful storage period. Monitoring should therefore follow an approved schedule linked to the process conditions. A routine that was adequate for one storage climate or turnover pattern may need review when residence time or temperature changes.

A measured decline in TBC should be evaluated before the system leaves its permitted range. The response belongs to the validated operating procedure and should account for distribution, carrier effects, and the state of the monomer. Adding inhibitor is not a guaranteed remedy for material already undergoing abnormal polymerization.

Temperature rise, pressure change, or other abnormal behavior requires the site's emergency response rather than reliance on an improvised chemical addition. The commercial benefit of TBC is controlled stability within a managed system. It does not eliminate the need for temperature control, analysis, equipment integrity, and a clear action plan.

STYRENE MONOMER PRODUCTION, STORAGE, AND TRANSPORT

4-tert-Butylpyrocatechol is an inhibitor associated with styrene, a major application for this chemical. The inhibitor helps preserve a monomer intended for later controlled polymerization into polystyrene, copolymers, or resin systems. The material may be present in a shipment's specification as a defined inhibitor content.

Receiving inspection should interpret that result alongside temperature, polymer content, appearance, and the other information required by the handling procedure. Transport changes residence time and thermal exposure. A protected batch at loading is not automatically unchanged at arrival, particularly where conditions deviate from the planned route or storage arrangement.

Storage equipment can have locations that are poorly represented by a single bulk sample. Dead spaces, poorly mixed zones, and condensed liquid deserve attention within engineering design and inspection practices. A monomer customer's downstream use also matters.

A polymerization plant may need to accommodate the supplied inhibitor content, while a distributor's priority is preserving quality and protection during turnover. Technical procurement should therefore specify both the inhibitor product and its intended role. Purchasing a concentrate for routine maintenance is different from selecting an entire storage protection strategy.

BUTADIENE, ISOPRENE, AND OTHER REACTIVE MONOMERS

4-tert-Butylpyrocatechol (TBC) is offered commercially for butadiene and several other reactive monomers. Their volatility, physical state, contamination sensitivity, and peroxide-related behavior differ from styrene and require individual handling guidance. A compressed or liquefied monomer introduces pressure and phase-distribution questions.

An inhibitor concentrated in the liquid phase may not protect vapor or condensate regions in the same manner. Peroxide formation and accumulation can create risks beyond ordinary polymer content. TBC should not be described as a universal peroxide destruction reagent or a reason to disregard a monomer's peroxide-control requirements.

Isoprene, chloroprene, vinyl acetate, and other listed applications also differ chemically. A supplier's broad application list provides a reason to investigate suitability, while a validated concentration and operating practice must be established for the specific stream. Carrier selection can be especially important where a monomer has tight moisture or solvent limits.

A commercially convenient inhibitor solution may introduce an impurity unacceptable to that process. For these applications, the buyer should provide the monomer identity and complete handling context. A generic request for TBC for unsaturated chemicals is not detailed enough to support a responsible technical recommendation.

DISTILLATION, PURIFICATION, AND VAPOR-PHASE LIMITATIONS

4-tert-Butylpyrocatechol (TBC) can be redistributed during distillation because it is much less volatile than many reactive monomers. The inhibitor may remain in a liquid residue while overhead condensate contains little or no corresponding protection. A protected feed therefore does not prove that every part of the separation system is inhibited.

Reboilers, liquid holdup, overheads, condensate paths, and stagnant locations need a process-specific protection assessment. The operating temperature and residence time differ from ordinary storage conditions. An inhibitor suitable for one service may need a different concentration, supporting system, or alternative chemistry under another process basis.

Oxygen availability can also differ under vacuum or changing gas-liquid conditions. The process assessment must consider whether the chemistry relied upon in storage remains effective during purification. Purified monomer can be more reactive operationally if a separation step has removed its protection.

Its subsequent collection, storage, and transfer require an approved strategy rather than an assumption that higher purity means lower risk. This discussion identifies engineering questions, not a universal dosing procedure. Distillation of reactive monomers should use validated design and operating controls developed for the actual system.

POLYSTYRENE, STYRENIC COPOLYMERS, AND LATEX MANUFACTURE

4-tert-Butylpyrocatechol (TBC) enters polymer production indirectly through inhibited monomer feedstocks. It can affect the early stages of an intended radical polymerization, making the incoming inhibitor level relevant to reproducible production. A supplied monomer with higher inhibitor content may show a different induction response under otherwise unchanged conditions.

The actual impact depends on initiator, temperature, feed strategy, and the reaction medium. Latex processes introduce an aqueous phase and additional ingredients that can alter inhibitor distribution. A bulk monomer analysis remains useful but does not fully describe the inhibitor's behavior after emulsification.

The manufacturer's goal is controlled conversion rather than indiscriminate inhibitor removal. Any adjustment needs to preserve handling protection until the material enters the validated reaction process. Different styrenic copolymers can respond differently because comonomers and additives change the reaction environment.

A response observed in one polymer grade should not automatically be assigned to the entire product family. Incoming specifications and batch records support troubleshooting. Linking monomer TBC content with conversion and induction observations helps distinguish inhibitor variation from initiator or process changes.

UNSATURATED POLYESTER, VINYL ESTER, AND REACTIVE RESIN SYSTEMS

4-tert-Butylpyrocatechol (TBC) can enter resin systems through inhibited styrene or other reactive components. That contribution should be counted when evaluating storage stability and later cure behavior. A resin producer may use a broader inhibitor package tailored to its chemistry.

TBC can be one relevant component, but a monomer stabilization practice should not be assumed to provide the complete resin's desired shelf life. Catalysts, peroxide initiators, accelerators, pigments, and fillers alter the reaction environment. A formulation that is stable as an unfilled base may show a different response after the commercial additive package is introduced.

Cure development should evaluate induction, gel behavior, conversion, and final properties under controlled conditions. An increased delay can be useful for working time but unacceptable if it prevents the product from reaching the required cure endpoint. Finished coatings, composites, adhesives, and castings therefore require their own evaluation.

The inhibitor's upstream role in monomer preservation does not establish a generic addition level for every resin application. Purchasing discussions should identify whether the requirement is neat TBC, a dosing concentrate, or a complete resin stabilization package. Those are different items with different performance and documentation needs.

ANALYTICAL CHEMISTRY AND SPECIALTY RESEARCH

4-tert-Butylpyrocatechol, also known as 4-tert-butylcatechol, is used in research involving oxidation, electrochemistry, and radical-related reactions. Its defined catechol structure makes it useful where a substituted diphenol is required for a specific experimental question. A research assay in a laboratory solvent does not necessarily predict industrial inhibition.

The test environment may omit oxygen transfer, contaminants, thermal history, or the monomer composition that dominates plant behavior. Reference material and general reagent material also serve different purposes. A calibration standard may need a certified concentration and traceability that a bulk industrial flake does not provide.

Oxidized products can be relevant to analytical interpretation. A method should distinguish the active compound from its transformation products if the result is used to make a process decision. The ingredient's effects in biological research are not evidence of a suitable consumer use.

In particular, observations involving pigmentation should not be converted into a recommendation for cosmetic skin-lightening formulations. Researchers should state exact identity, purity basis, and solution preparation conditions. This avoids treating different commercial concentrates as equivalent merely because each contains the abbreviation TBC.

COMPARISON WITH MEHQ AND HYDROQUINONE

4-tert-Butylpyrocatechol (TBC) has a substituted catechol structure that differs from those of MEHQ and hydroquinone, established phenolic inhibitors in suitable applications. Their effectiveness depends on the monomer, oxygen conditions, concentration, temperature, and process objective. An inhibitor selected for an acrylate supply chain should not be replaced automatically by one associated with styrene.

A family resemblance in chemical mechanism does not prove equal storage protection or compatibility. TBC's practical advantage is its established role in certain monomer stabilization systems and the availability of useful commercial delivery forms. The alternatives may provide a better balance in another substrate or processing environment.

Equal mass concentrations are not a complete comparison because molecular weights and reaction pathways differ. Performance should be tested against the actual approved conditions rather than ranked through ppm values alone. Color, solubility, analytical method, and downstream cure influence can also affect selection.

An inhibitor with strong screening performance may still be unsuitable if it introduces an unacceptable impurity or formulation response. A substitute should be qualified as part of the full protection strategy. The technical decision belongs to the actual monomer and process, not a general claim that one inhibitor is strongest in every situation.

COMPARISON WITH BHT, TBHQ, AND OTHER ANTIOXIDANTS

4-tert-Butylpyrocatechol differs from BHT, a hindered monophenol, and tert-butylhydroquinone, which has a different arrangement of two hydroxyl groups. Neither is a synonym for 4-tert-Butylpyrocatechol despite sharing tert-butyl and phenolic terminology. Their common antioxidant descriptions can obscure application differences.

Performance in food-related, lubricant, rubber, or finished-polymer systems does not establish suitability for reactive monomer storage. TBC may be preferred when the approved monomer-handling system is designed around its behavior. Another antioxidant may be appropriate where the aim is long-term oxidation control in a different product matrix.

A commercial comparison should include solubility and transformation products as well as inhibition. Residual color, impurity effects, and reaction with other additives can determine whether a candidate fits the manufacturing brief. Regulatory and safety information also differs between exact substances and grades.

An approval or certification held by one antioxidant cannot be transferred to TBC because the molecules contain similar functional groups. The useful purchasing question is what the material must accomplish in a defined environment. That question supports an evidence-based comparison without a misleading universal ranking of phenolic chemicals.

OXYGEN-INDEPENDENT AND SPECIALIZED INHIBITOR SYSTEMS

4-tert-Butylpyrocatechol (TBC) is not the only inhibitor option for processes where oxygen availability differs from ordinary storage. Such alternatives can be relevant to purification or high-temperature service, but they require their own qualification. Nitroxide, phenothiazine, or other specialized systems are not interchangeable with TBC by name or equal mass.

Their compatibility, temperature response, consumption, and analytical control can be substantially different. A need for different oxygen behavior should be stated explicitly in the technical brief. Choosing an alternative on that basis still requires checking the entire process rather than only one attractive characteristic.

Mixed inhibitor packages can introduce interactions that are not predicted from each component separately. The package should be evaluated as a complete composition, including carriers and impurities. The objective may also differ between normal operation and emergency protection.

A routine storage inhibitor should not be credited with arresting every runaway, and emergency systems require a separate engineered basis. Supplier guidance is useful when it addresses the exact service. A broad catalogue list of inhibited monomers is insufficient to establish a specialized distillation or abnormal-condition procedure.

SOLID FLAKES AND COMMERCIAL SOLUTIONS

4-tert-Butylpyrocatechol in solid form offers a high active-content basis with no intentionally added liquid carrier. Its practical use requires suitable weighing, transfer, and dissolution or incorporation arrangements for the intended process. A concentrate can simplify liquid dosing and improve repeatability where the carrier is compatible.

It also introduces additional mass that must be included in the monomer's impurity and process balance. Commercial products include methanol-based, aqueous, and aromatic-solvent formulations at defined nominal strengths. Those product descriptions are not generic instructions to reproduce the commercial formulations from raw ingredients.

A concentrated aqueous product may have phase behavior unlike a dilute solution prepared by simple ambient mixing. Temperature, composition, and the supplier's formulation determine its handling, so a water-based product name should not be interpreted as unlimited water solubility. Carrier flash point, toxicity, moisture contribution, and compatibility affect selection.

A convenient metering product can be unsuitable if its carrier compromises downstream polymerization or an impurity specification. Compare solid and solution options on active inhibitor delivered and total process consequences. Price per kilogram of product does not establish which option provides the lowest cost or best technical fit.

SELECTING AN APPROPRIATE QUALITY GRADE

4-tert-Butylpyrocatechol grade selection should support the specified monomer or resin application and its handling arrangement. Assay is important, but it does not answer every question concerning dissolution, carrier, water, color, or contaminants. A high-assay solid may be useful when carrier introduction must be minimized.

A liquid concentrate may suit automated metering if its concentration, stability, and carrier meet the process requirements. Analytical or research use may require a reagent or reference standard with a defined method and purity basis. That choice should not be assumed to provide the bulk supply or functional qualification needed for routine industrial dosing.

Color-sensitive monomers or downstream resins may require a tighter impurity or color specification. A grade acceptable for a darker product can still be unsuitable for a clear commercial formulation. A purchasing specification should state whether the active concentration is nominal, typical, or guaranteed.

The basis affects dosing calculations and the review of a delivery batch. The most restrictive specification is not automatically the best. Limits should address demonstrated process needs so that qualification protects performance without adding unnecessary cost or excluding suitable sources.

ASSAY, WATER, COLOR, AND INSOLUBLE MATTER

4-tert-Butylpyrocatechol assay results should be interpreted with the analytical method and reporting basis. A chromatographic area percentage, a titration result, and an active-content statement for a commercial solution are not automatically equivalent. Water can be an intended carrier or an unwanted impurity.

The specification must make that distinction clear because the same water percentage can be acceptable in one dosing product and unsuitable in another. Color is useful as a quality attribute but is not a substitute for active inhibitor measurement. Oxidation, carrier, trace contaminants, and concentration can all influence appearance.

Insoluble matter can disrupt filters or metering equipment and complicate incorporation. A small visible residue may matter even when the main compound's assay remains within specification. Trace metals or other contaminants may affect monomer stability or downstream color.

Where relevant, define the specific limits and methods rather than requesting an undefined contaminant-free product. The incoming standard should link each parameter to its purpose. This gives quality staff a practical basis for evaluating a deviation and avoids accepting material that meets one headline assay while failing an important process requirement.

TDS, SDS, COA, AND SUPPORTING INFORMATION

4-tert-Butylpyrocatechol technical data sheets describe the product and relevant technical characteristics, including the supplied form and concentration. Typical values should not be converted into guaranteed purchasing limits unless the supplier's specification supports that interpretation. The SDS supplies the hazard and handling information for the exact solid or solution grade.

A methanol-containing concentrate has carrier hazards beyond those of the active ingredient, while an aqueous product still requires review of the complete mixture. The COA connects a batch with analytical results or conformity statements. Product code, lot number, concentration, and the relevant acceptance limits should align with the material physically delivered.

Additional documentation may concern origin, regulatory coverage, carrier declaration, impurities, or application-specific suitability. Availability must be confirmed for the exact offer rather than promised generically under the product name. A monomer supplier's handling guide addresses a different question from the inhibitor's TDS.

Both can be relevant, because chemical product information alone does not define the operating conditions needed to protect the stored monomer. Complete document review before routine dosing qualification. Resolving an ambiguous active concentration or incompatible carrier after production approval can create avoidable process and commercial disruption.

MEASURING TBC IN MONOMER

4-tert-Butylpyrocatechol (TBC) measurement must use a method suitable for the monomer matrix and concentration range. A method developed for a concentrated dosing product may not provide the same accuracy at trace levels in a shipment. Colorimetric and chromatographic approaches can answer different analytical questions.

Method interference, response to related substances, and detection capability need consideration where the result governs an operating decision. The sample should represent the material being evaluated. Poor mixing, phase separation, or sampling from an unrepresentative location can produce a plausible laboratory result that does not describe the actual bulk condition.

Calibration and reporting units should be unambiguous. Parts per million by mass, milligrams per kilogram, and a volume-based concentration are not interchangeable without the relevant conversion information. A result should be reviewed with uncertainty and the approved acceptance range.

Treating a near-limit measurement as an exact number can produce an unjustified dosing or release decision. Where monomer condition is changing, inhibitor analysis is one part of the picture. Temperature, polymer content, oxygen conditions where relevant, and other approved checks provide the context needed to interpret protection.

PPM, PERCENTAGE, AND ACTIVE-CONTENT CALCULATIONS

4-tert-Butylpyrocatechol concentrations expressed as one ppm by mass correspond to one milligram per kilogram. Ten ppm therefore equals 0.001% by mass, a conversion that is useful when comparing trace monomer content with a concentrate expressed in percentage terms. A calculation should distinguish target total inhibitor from the additional amount required.

If the initial concentration is already known, the increment concerns the difference rather than the full target concentration. For an approximate small-addition calculation, the active inhibitor mass equals monomer mass multiplied by the required ppm increment and divided by one million. Dividing that active mass by the product's active fraction gives the commercial product quantity.

For example, an arithmetic increment of 5 ppm across 100,000 kg corresponds to 0.50 kg of active TBC. An 85% product would supply that amount through approximately 0.588 kg of product, before accounting for any exact final-mass correction. These numbers illustrate unit conversion and do not establish a safe increment or storage target.

The permitted concentration and response procedure must come from the validated monomer-handling basis. An exact final-mass calculation can be appropriate where precision is required. If M is initial mass, ci and ct are initial and target active mass fractions, and f is concentrate active fraction, the required product mass is M multiplied by (ct minus ci) divided by (f minus ct).

STARTING FORMULAS AND COMPOSITION EXAMPLES

4-tert-Butylpyrocatechol examples below are calculation or development starting points for qualified industrial work. They are not operating procedures for monomer storage, compressed-gas handling, distillation, or emergency polymerization control. Percentage examples total 100% by mass, and the carrier belongs in the complete composition.

The chosen strengths illustrate accounting and qualification rather than reproduce a guaranteed commercial product or establish universal solubility. Before using a concentrate concept, verify dissolution, temperature response, carrier suitability, and the actual grade's SDS. Before using a monomer composition, establish the applicable protection strategy and operating limits separately. This distinction makes the formulas useful to procurement and process specialists. It provides a clear basis for comparing active content without implying that arithmetic alone establishes safe inhibition.

STARTING FORMULA: DILUTE METHANOL-BASED ANALYTICAL STOCK

- Qualified TBC: 1.00%
- Suitable analytical methanol: 99.00%
- Total: 100.00%
- Nominal active concentration before assay correction: 10,000 ppm by mass

4-tert-Butylpyrocatechol analytical stock described here illustrates a dilute solvent preparation for an analytical method that accepts methanol. It is not a recommendation for dosing methanol into every monomer stream or a certificate of solution stability. Use the actual standard purity and the method's preparation requirements when calculating concentration.

A bulk flake with nominal assay is not automatically a certified reference material for quantitative calibration. The complete mixture requires controls for methanol as well as TBC. Solution dating and storage should follow the validated analytical procedure rather than a generic raw material shelf life.

STARTING FORMULA: AROMATIC-CARRIER DISSOLUTION SCREEN

- Qualified TBC: 5.00%
- Suitable toluene: 95.00%
- Total: 100.00%
- Nominal active concentration before assay correction: 50,000 ppm by mass

4-tert-Butylpyrocatechol in this example provides a dilute screening basis for assessing compatibility in a selected aromatic carrier. It is not a guaranteed dosing-concentrate recipe, and complete dissolution and temperature stability must be demonstrated. Compare clarity, residue, and concentration after the relevant storage conditions.

A concentrate that dissolves initially can still develop crystals or lose suitability through contamination or carrier loss. Toluene's suitability depends on the receiving process and its impurity limits. A carrier commonly used in one commercial inhibitor product should not be treated as acceptable in every monomer or resin system.

STARTING FORMULA: NOMINAL 10 PPM STYRENE COMPOSITION BASIS

- Styrene monomer basis: 99.9990%
- Active TBC basis: 0.0010%
- Total: 100.0000%
- Active inhibitor expressed by mass: 10 ppm

4-tert-Butylpyrocatechol in this composition illustrates the conversion of a trace inhibitor value into a percentage mass basis. It is not a recommendation to operate every styrene storage system at 10 ppm or evidence of protection without the required oxygen and temperature conditions. Commercial styrene already containing inhibitor should not receive the full listed amount as an additional dose.

The calculation must begin with measured current content and the approved target or adjustment requirement. Any incorporation and subsequent confirmation belong to the site's validated procedure. Abnormal monomer behavior must be addressed through the appropriate response plan rather than this illustrative composition.

STARTING FORMULA: NOMINAL 15 PPM STYRENE COMPOSITION BASIS

- Styrene monomer basis: 99.9985%
- Active TBC basis: 0.0015%
- Total: 100.0000%
- Active inhibitor expressed by mass: 15 ppm

4-tert-Butylpyrocatechol in this second composition illustrates the difference between total active content and percentage notation at trace concentration. It supports calculations and comparisons without defining a universal allowable storage period. A change from one concentration to another requires evaluating the approved monomer conditions and the downstream requirement.

More inhibitor does not remove oxygen dependence or compensate automatically for excessive temperature. When comparing supplier shipments, record whether the result concerns total TBC, the method used, and the actual sampling conditions. That context is more useful than treating a nominal ppm number as a complete quality statement.

STARTING BASIS: 85% COMMERCIAL CONCENTRATE ACCOUNTING

- Commercial product quantity: 1.000 kg
- Active TBC at a nominal 85% mass fraction: 0.850 kg
- Carrier and other components at the corresponding balance: 0.150 kg
- Active concentration: Verified against the actual sales specification and batch information

4-tert-Butylpyrocatechol concentrate accounting here represents a purchased concentrate rather than instructions to prepare an 85% mixture. A methanol-containing grade and an aqueous grade require separate compatibility and handling review. The carrier mass enters the receiving process along with the active.

Where moisture or solvent impurities matter, include that contribution in the final material balance. If the actual delivered active content differs within an approved range, use the appropriate correction in the dosing calculation. Do not assume the product name supplies an exact measured concentration for every batch.

STARTING BASIS: 44% AROMATIC COMMERCIAL CONCENTRATE

- Commercial product quantity: 1.000 kg
- Active TBC at a nominal 44% mass fraction: 0.440 kg
- Carrier and other components at the corresponding balance: 0.560 kg
- Carrier identity: Confirmed from the exact commercial product's documents

4-tert-Butylpyrocatechol accounting in this example shows why product quantity and active inhibitor quantity are different. A lower-strength solution delivers more carrier per unit of active, which can matter to impurities, logistics, and downstream processing. A commercial solution's clarity and handling properties come from its complete formulation and manufacture.

They cannot be assumed for an improvised mixture that happens to use the same nominal percentages. Compare offers using delivered active mass as well as carrier acceptability. A lower price per kilogram of solution may not provide a lower cost per unit of useful inhibitor.

STARTING BASIS: MONOMER-FEED BLENDING CALCULATION

- Feed A mass: 40,000 kg
- Feed A measured TBC: 12 ppm by mass
- Feed B mass: 60,000 kg
- Feed B measured TBC: 18 ppm by mass
- Total feed mass: 100,000 kg
- Calculated mixed TBC, assuming no loss or reaction: 15.6 ppm by mass

4-tert-Butylpyrocatechol weighted average is calculated from active mass in each feed, not the simple average of the two concentrations. In this example, the larger high-concentration feed contributes more strongly to the mixed result. The assumption of no consumption or segregation must be appropriate to the actual operation.

Confirming the mixed material by the approved analytical method may be necessary before an operational decision. The calculated average says nothing by itself about oxygen conditions, temperature, or the state of either feed. Blending arithmetic cannot establish that material with abnormal polymerization indicators has become suitable for storage.

DISSOLUTION, MIXING AND CONCENTRATE VALIDATION

4-tert-Butylpyrocatechol concentrates should remain uniform across the temperatures and residence times expected between preparation and consumption. A clear solution immediately after mixing does not establish that the same material will remain clear overnight, during transport, or in a colder dosing cabinet. For a dissolution study, record the exact solvent composition, raw-material assay, sample temperature, observation time, and whether the sample was agitated before inspection.

Comparing these records with an analytical result distinguishes incomplete dissolution from a genuinely homogeneous solution whose appearance simply differs from another grade. Crystallization can change the delivered concentration even when the total amount of inhibitor inside the container has not changed. If solids settle while a pump draws primarily liquid, the receiving monomer may receive a different active concentration from the value calculated from the original recipe.

Heating to redissolve crystals requires an approved procedure that considers the carrier, container, ventilation, and thermal stability of the mixture. A published melting point for pure 4-tert-Butylpyrocatechol is not an instruction to heat every concentrate or packaged product to that temperature. The carrier must fit both the immediate dosing operation and the downstream manufacturing process.

Methanol, water, and aromatic hydrocarbons introduce different effects on analytical methods, phase behavior, volatile content, material compatibility, and product specifications. For a new concentrate, a useful qualification package combines appearance observations with assay at representative sampling positions and storage conditions. A viscosity or density measurement can also help determine whether the installed metering equipment can deliver the proposed solution consistently.

Container residues deserve attention because a nominally empty package can retain concentrated inhibitor or solvent. Handling and disposal arrangements should account for these residues instead of treating the package as clean merely because the bulk liquid has been removed.

METERING ACCURACY AND DISTRIBUTION IN THE RECEIVING MATERIAL

4-tert-Butylpyrocatechol purchase assay alone does not guarantee an accurate delivered dose. Meter calibration, solution density, pump performance, instrument units, and actual flow determine how much active material reaches the receiving stream. A volumetric pump setting must be converted using the density of the actual concentrate at the relevant temperature.

Substituting the density of pure TBC, its carrier, or a different commercial formulation can introduce a systematic dosing error. Distribution is equally important because a laboratory result from one accessible location may not represent the entire receiving volume. Mixing arrangements, residence time, injection location, and sampling position should be considered together when the engineering team establishes its operating procedure.

The concentration calculation should distinguish mass flow from volume flow and active ingredient from total concentrate. A control display labeled only with a number such as 15 or 85 leaves room for confusion unless the associated units and basis are explicit. For traceability, the dosing record can identify the concentrate batch, measured or certified active content, dosing period, receiving material quantity, and instrument status.

This provides a practical route for investigating deviations without assuming that the raw material itself caused every unexpected result. A change in carrier or active concentration may require recalibration even when the chemical identity remains unchanged. The replacement solution can have different flow characteristics, and an unchanged pump setting may therefore produce a different active delivery rate.

RECEIVING INSPECTION AND REPRESENTATIVE SAMPLING

4-tert-Butylpyrocatechol received as a neat inhibitor requires different acceptance criteria from incoming inhibited monomer. One is a chemical raw material whose identity, assay, physical condition, and packaging must be checked; the other is a reactive feedstock whose condition depends on its storage and transport history as well as its inhibitor content. For solid para-tert-butylcatechol, receiving inspection can address packaging integrity, lot identification, visible contamination, unexpected agglomeration, and agreement with the agreed physical form.

Sampling should avoid introducing moisture or foreign particles that could alter subsequent testing or handling. For a commercial solution, verify the declared carrier and active concentration before using the product in an established dosing calculation. A solution with the correct inhibitor identity but a different solvent is not automatically interchangeable with the approved supply.

Representative monomer sampling requires a site procedure appropriate to the material, pressure, temperature, and exposure hazards. The sample label should capture enough context to interpret the result, including sampling location and time relative to delivery, circulation, or a previous addition. Sample containers and holding conditions can influence the measured result, especially when the analytical method depends on a stable matrix.

The laboratory should define acceptable delays, storage conditions, and preparation steps rather than relying on an informal practice developed for a different monomer. A retained sample can support investigation of a disputed batch, but its relevance decreases if its storage conditions are undocumented. Recording the chain of custody and retention conditions makes the sample more useful than merely placing an unlabelled bottle on a shelf.

FUNCTIONAL VALIDATION AND DOWNSTREAM PROCESS COMPATIBILITY

4-tert-Butylpyrocatechol chemical assay establishes how much measurable inhibitor is present under the selected analytical method. Functional inhibition depends additionally on the monomer, oxygen conditions, temperature, contaminants, and initiating species, so assay and performance should answer different questions in a qualification program. Where functional testing is needed, it should use a validated laboratory approach with equipment and supervision suitable for reactive chemicals.

Informal heating of inhibited monomer in an open vessel can create misleading results and uncontrolled exposure rather than a meaningful measure of industrial protection. The test design should reflect the actual decision being made, such as comparing two qualified grades or assessing a carrier change. A test with different oxygen availability or a different impurity profile may rank materials in a way that does not translate to the production system.

In polymer manufacture, residual p-tert-butylcatechol can influence induction time and initiator demand. A feedstock that is well suited to protected storage may therefore require a downstream process adjustment, but that adjustment must preserve the established controls for handling the reactive feed. For resin development, evaluate gel time alongside final conversion, mechanical properties, color, and storage behavior.

Optimizing only one laboratory endpoint can produce a formulation that appears convenient during testing but behaves poorly during filling, transport, or customer use. An inhibitor-removal step introduces its own risks and quality questions because the treated monomer may have less protection afterward. Such a step belongs within an engineered process with defined residence time, equipment cleanliness, verification, and disposition criteria.

TROUBLESHOOTING LOW ASSAY, COLOR CHANGE AND PRECIPITATION

4-tert-Butylpyrocatechol results showing lower inhibitor content can indicate consumption, dilution, sampling variation, incomplete dissolution, or analytical interference. Investigating these possibilities systematically is more useful than immediately attributing the result to defective raw material or assuming that an additional dose will resolve the underlying cause. Start by confirming the sample identity, calculation basis, calibration status, and method suitability for the matrix.

An incorrect dilution factor or confusion between concentrate assay and monomer concentration can create an apparent deviation larger than the actual chemical change. If the analytical result is confirmed, review temperature history, elapsed storage time, mixing conditions, and the composition of any recent additions. These records help establish whether the change follows normal inhibitor consumption or represents an unexpected operating condition requiring a different response.

Color development may involve oxidation products, trace metals, impurities, or interactions with the surrounding formulation. A darker appearance alone cannot quantify remaining inhibition, and an unchanged pale color does not prove that the reactive material is adequately protected. Precipitation should be investigated by identifying the solid rather than assuming that every particle is crystalline TBC.

The material could include contamination, a reaction product, corrosion debris, or another component whose solubility has changed. Filtering an unexplained solid can improve visual clarity while leaving the underlying cause unresolved. It may also change the inhibitor distribution if the removed material contains active ingredient, so the filtered liquid should not be accepted solely because it looks cleaner.

When two lots perform differently, compare impurity profiles and carrier composition as well as headline purity. Minor components can matter in sensitive applications even when both lots satisfy the same broad assay specification.

STORAGE OF THE INHIBITOR AND PACKAGING SELECTION

4-tert-Butylpyrocatechol should be stored according to the specific supplier safety data sheet and product instructions. The requirements for a solid grade, an aqueous commercial product, and a flammable solvent concentrate can differ substantially even though all contain the same active molecule. Keep containers identified and closed when they are not in use, and protect the material from contamination.

Packaging should be compatible with both the active chemical and any solvent, including closures, seals, liners, and transfer accessories that contact the product. Temperature management should consider the physical form and the conditions encountered in the warehouse or transport route. A material that softens, cakes, or develops crystals may become difficult to handle or sample even if its chemical identity remains unchanged.

Storage instructions for neat TBC must not be confused with the oxygen strategy for inhibited monomers. The suitability of a monomer atmosphere depends on the monomer-specific inhibition mechanism and engineered controls, rather than a general preference for keeping every chemical away from air. A manufacturer-assigned shelf life or retest date applies to the defined grade, package, and storage conditions.

It should not be replaced with a generic period copied from another product or inferred from the fact that the material is a solid. If a package has been opened, record the date and follow the site's requirements for resealing, secondary containment, and requalification. The remaining contents may experience conditions that differ from those used to support the original unopened-package shelf life.

Packaging size affects handling frequency, dosing convenience, and the quantity exposed during transfer. Selecting a larger container solely to reduce price per kilogram can increase residual waste or operational difficulty when consumption is infrequent.

OCCUPATIONAL SAFETY AND EXPOSURE CONTROL

4-tert-Butylpyrocatechol has published classifications for the neat substance that include harmful effects from swallowing or skin contact, corrosive effects, and skin sensitization. These characteristics make industrial exposure control a necessary part of using the inhibitor, even when its final concentration in a monomer is measured in parts per million. Concentrated handling presents a different exposure situation from handling a diluted downstream product.

The safety assessment should consider the form actually being transferred, including dust from a solid and vapor or splash hazards from a solvent-based solution. Engineering controls, suitable transfer equipment, and procedures that minimize direct contact should be selected before relying on personal protective equipment. Glove selection requires chemical compatibility with the complete formulation because a glove suitable for the solid may be unsuitable for its carrier solvent.

Eye and face protection, protective clothing, and access to appropriate emergency facilities should follow the site assessment and current SDS. Respiratory protection, if required, must be selected and managed within a suitable occupational program rather than chosen from a generic product description. Skin sensitization means that repeated exposure can have consequences beyond immediate irritation.

Personnel should report suspected exposure effects promptly and follow the workplace medical and incident procedures without continuing contact merely because the visible symptoms initially appear minor. Accidental exposure requires the first-aid instructions in the supplied SDS and appropriate medical evaluation. Improvised chemical neutralization on the body can add injury and should not replace the specified response.

The industrial role of tert-butylcatechol does not support its use as a consumer skin treatment. Reports involving occupational skin effects are safety information, not evidence that the material is suitable for cosmetic depigmentation or personal-care formulation.

Where a process recovers monomer or solvent, assess whether inhibitor partitions into a residue, a recovered stream, or another phase. This mass balance matters for both residue characterization and the suitability of the recovered material for reuse.

A release response should use the site's trained personnel, containment resources, and notification arrangements. The appropriate cleanup method depends on the quantity, physical form, carrier, and surrounding equipment, so a single generic absorbent instruction cannot cover every commercial grade.

ABNORMAL MONOMER CONDITIONS AND LIMITS OF INHIBITOR ADDITION

4-tert-Butylpyrocatechol (TBC) is part of a prevention strategy and should not be presented as a guaranteed remedy for an abnormal polymerization event. Rising temperature, pressure changes, unexpected polymer formation, or other warning signs require the established emergency response for the material and installation. Adding inhibitor to a poorly mixed or rapidly reacting system may not distribute it where protection is needed.

The addition can also introduce solvent or involve transfer operations that are inappropriate during an abnormal condition. An assay result obtained before an excursion does not establish the current condition of the entire inventory. Monitoring data, process history, and the response plan are essential because reaction rates and local conditions can change faster than a routine laboratory turnaround.

Emergency arrangements should be developed by qualified personnel with knowledge of the monomer and the installed equipment. This includes clear decision authority and communication requirements, rather than relying on a product page to prescribe a rescue dose or atmosphere change.

COST PER ACTIVE KILOGRAM AND TOTAL PROCUREMENT VALUE

4-tert-Butylpyrocatechol prices for solid and solution grades require comparison on an active-content basis. A lower delivered price per kilogram of concentrate may correspond to a higher cost per kilogram of actual 4-tert-Butylpyrocatechol after the carrier fraction is included. For a product with active mass fraction f, the simple active-equivalent price is the product price divided by f.

This calculation is a useful starting point, but it excludes transport, packaging, labor, dissolution equipment, solvent management, and losses during transfer. A ready-to-use solution may reduce preparation work and variability when its carrier and concentration match an approved process. Conversely, solid material may suit a facility that already has qualified dissolution equipment and wants control over the solvent choice.

The commercial comparison should include the quantity that can be consumed before retesting or expiry, not only the purchase quantity. Residual concentrate, damaged packaging, or repeated small transfers can change the effective cost of a seemingly economical order. Quality documentation can also have operational value because it supports acceptance and reduces avoidable testing disputes.

A clear specification and consistent batch identification make procurement easier to coordinate with production and the laboratory. Delivery reliability matters when the inhibitor supports a continuous monomer operation, but it should be established through actual supply arrangements. General marketing language cannot substitute for an agreed lead time, packaging plan, and contingency approach.

SUPPLIER QUALIFICATION AND CHANGE CONTROL

4-tert-Butylpyrocatechol supplier qualification should establish the exact chemical identity, approved grade, physical form, carrier if present, and specification limits. The qualification should also identify which documents accompany a shipment and which supporting records are available on request. A certificate of analysis should correspond to the supplied batch and report the agreed release parameters.

A general product brochure may describe typical properties, but it is not a replacement for batch-specific conformity information. Changes in production route, carrier, assay method, impurity limits, manufacturing site, or packaging can affect a qualified application. The supply agreement should define how relevant changes are communicated and when additional review or sample evaluation is needed.

Claims such as high purity, industrial grade, or premium inhibitor have limited purchasing value without measurable criteria. Buyers should translate these descriptions into an agreed assay basis, impurity requirements, appearance limits, and relevant method details. A technical enquiry is more effective when it identifies the monomer or process, expected consumption, current dosing form, and any prohibited carriers.

This allows the supplier to discuss an appropriate material instead of offering a chemically correct but operationally unsuitable package. Retaining the approved specification and sample evaluation results provides a reference for future orders. It also helps distinguish a legitimate grade change from a simple variation in commercial naming or catalogue description.

FREQUENTLY ASKED QUESTIONS ABOUT 4-TERT-BUTYLPYROCATECHOL

What is 4-tert-Butylpyrocatechol used for?
It is an industrial inhibitor used to help control unwanted free-radical polymerization in selected reactive monomers and related processing systems. Suitability depends on the particular monomer, operating conditions, and approved inhibitor strategy.

Is TBC the same chemical as 4-tert-butylcatechol?
Yes, TBC commonly refers to 4-tert-butylcatechol in this industrial context. The CAS number 98-29-3 provides a clearer identity reference when abbreviations or commercial names could be ambiguous.

What are the CAS and EC numbers?
The CAS number is 98-29-3, and the EC or EINECS number is 202-653-9. These identifiers apply to the chemical substance and do not describe the solvent composition of a commercial solution.

What is the molecular formula?
The molecular formula is C10H14O2, with a molar mass of approximately 166.22 g/mol. The structure combines a catechol ring with a tert-butyl substituent.

Why does the molecule contain two hydroxyl groups?
The two hydroxyl groups occupy adjacent positions on the aromatic ring and contribute to its characteristic catechol chemistry. Their arrangement is relevant to radical interception, oxidation behavior, and interactions with other chemical species.

Is the product normally a solid or a liquid?
The neat substance is normally supplied as a solid, including flakes or other particulate forms. Commercial products can also be solutions whose liquid behavior depends on their solvent and concentration.

What melting point should a buyer expect?
Published values are commonly around 52 to 58 degrees Celsius, with differences arising from source, method, and grade. The purchased product specification should define the relevant acceptance criterion instead of treating a literature interval as a guaranteed release limit.

Does TBC dissolve in water?
Water compatibility must be evaluated for the intended concentration and temperature, and commercial aqueous grades demonstrate that a blanket statement of complete water incompatibility would be misleading. An aqueous concentrate should still be qualified for dilution, phase behavior, and its effect on the receiving system.

Can methanol be used as a carrier?
Methanol-based commercial grades are available, and methanol can be suitable for certain qualified applications. Its toxicity, flammability, downstream limits, and compatibility must be included in the assessment.

Can toluene be used as a carrier?
Aromatic-carrier commercial formulations exist, including toluene-based products. Their suitability depends on solvent restrictions, handling arrangements, and the process receiving the inhibitor.

Does a higher assay always give better inhibition?
A higher assay provides more active substance per unit mass but does not automatically create better protection under every operating condition. Distribution, oxygen availability where required, temperature, and initiating contaminants can be decisive.

Does TBC need oxygen in styrene?
Effective TBC-based styrene inhibition depends on suitable dissolved oxygen conditions as part of the approved storage strategy. An atmosphere change must therefore be assessed using the styrene supplier's guidance and the installation's engineered safety requirements.

Should nitrogen blanketing always be used?
A blanket instruction to exclude oxygen can conflict with the requirements of an oxygen-dependent inhibitor system. The appropriate atmosphere is monomer-specific and must balance inhibition requirements with flammability and other process hazards.

Can the styrene oxygen strategy be copied to butadiene?
No, butadiene has distinct pressure, peroxide, and handling considerations that require its own approved guidance. Sharing an inhibitor name does not make two monomers operationally interchangeable.

Is there a universal safe TBC dosage?
There is no universal concentration that establishes safe storage for every monomer, temperature, inventory history, and equipment configuration. A qualified dosage belongs within a complete operating strategy rather than functioning as an isolated safety guarantee.

What does 10 ppm by mass mean?
It means 10 mass units of active inhibitor per million mass units of the final mixture. The required concentrate quantity additionally depends on its active fraction and on any inhibitor already present.

Should existing inhibitor be included in the calculation?
Yes, the measured starting concentration should be considered when calculating an intended increment. Assuming that a delivered monomer contains no inhibitor can lead to unnecessary addition and a different downstream induction time.

How is an 85 percent concentrate different from pure TBC?
An 85 percent product contains nominally 0.85 kg of active ingredient per kilogram of concentrate, with the remainder consisting of the declared carrier and any specification-defined components. The concentrate mass must be corrected for active content in dosing calculations.

Can a clear solution still have the wrong concentration?
Yes, visual clarity does not establish active assay or confirm that the correct carrier and dilution were used. Analytical verification and documented preparation records answer questions that appearance alone cannot resolve.

Why do crystals matter in a dosing solution?
Crystals can cause the liquid phase delivered by a pump to differ from the overall composition of the container. They may also indicate a temperature or compatibility issue that needs investigation before the solution is accepted for use.

Does darkening prove the inhibitor has failed?
Darkening can arise from several chemical changes and does not directly quantify remaining inhibition. Interpret it alongside assay, impurities, storage history, and the condition of the receiving monomer.

Can TBC protect a distillation vapor space?
Its relatively low volatility can limit delivery of inhibitor to vapor and condensate regions. Distillation protection therefore requires an engineering assessment of the relevant phases and equipment surfaces.

Will residual TBC affect polymerization later?
Residual inhibitor can influence the induction period and other aspects of a downstream radical polymerization. The manufacturing process should account for this effect without compromising the handling controls for the feedstock.

Can the inhibitor be removed before polymerization?
Some engineered processes include inhibitor removal, but the resulting material may become more vulnerable to unwanted reaction. Removal, verification, residence time, and subsequent handling need to be addressed together.

Is TBC interchangeable with MEHQ?
Both can act as inhibitors in suitable applications, but their performance, solubility, oxygen response, and downstream effects are not identical. Replacement requires application-specific evaluation rather than a name-based substitution.

Is tert-butylcatechol the same as BHT?
No, BHT has a different molecular structure and a different typical application profile. Similar antioxidant terminology does not establish equal monomer-inhibition performance.

Does the product have a verified cosmetic INCI name?
A cosmetic INCI designation is not established here for this industrial raw material. Its use as a monomer inhibitor must not be converted into an unsupported recommendation for personal-care products.

Which grade is appropriate for a sensitive process?
Choose a grade whose assay, impurity profile, carrier, and documented methods meet the actual process requirements. High headline purity is useful only when the remaining specification also addresses the application's important constraints.

What should the TDS contain?
The technical data sheet should describe the supplied grade, physical form, typical or specified properties, and relevant application guidance. It should distinguish indicative data from contractual acceptance limits.

What should the COA confirm?
The certificate of analysis should identify the batch and report the agreed conformity results using the specified basis. It should be reviewed against the approved purchasing specification before release for use.

Why is the SDS needed if the dosage is very low?
The SDS addresses the hazards of the supplied material, which may be concentrated and may contain a hazardous carrier. Personnel preparing or transferring the inhibitor can encounter a different exposure from that associated with the diluted final monomer.

Can the material cause skin sensitization?
Published hazard classifications include skin sensitization for the neat substance. Preventing contact and following the site exposure-control procedure are therefore important even when no immediate irritation is noticed.

What information is needed for a quotation?
Provide the exact chemical name, desired physical form or carrier, required quantity, destination, and essential specification limits. Including the intended application helps identify whether the proposed grade can support the qualification process.

How should solid and solution prices be compared?
Normalize the prices to active inhibitor content and then consider preparation, transport, packaging, waste, and equipment costs. A comparison based only on gross kilograms can overlook the carrier fraction and practical handling expenses.

Can additional TBC stop an abnormal polymerization event?
An additional dose is not a guaranteed response to an abnormal reaction and can be ineffective if distribution or reaction conditions are unfavorable. Follow the installation's emergency plan rather than improvising from a routine dosing calculation.

What should be checked after a supplier changes the carrier?
Review dosing calculations, metering calibration, solvent compatibility, analytical suitability, and downstream product limits. The unchanged active identity does not remove the need to qualify the modified formulation.

Can a product page replace a process safety assessment?
A product page can explain chemistry, purchasing criteria, and formulation considerations, but it cannot establish the safe operating envelope of an installation. That decision requires the actual monomer, equipment, process conditions, and qualified engineering review.

4-TERT-BUTYLPYROCATECHOL SUPPLY FROM ATAMAN KIMYA

4-tert-Butylpyrocatechol enquiries to Ataman Kimya should describe the application in terms of the problem the inhibitor must address. Identifying the reactive monomer, the intended dosing form, and any carrier restrictions gives the enquiry a technical basis that is more useful than requesting TBC by name alone. Ask for confirmation of the offered grade, active concentration, packaging, batch documentation, and the applicable safety data sheet.

If a specific purity or impurity requirement is important, include it in the enquiry so that the quotation and sample evaluation can be assessed against the same criteria. A practical supply discussion should connect purchasing requirements with laboratory acceptance and plant handling. This includes the amount needed for evaluation, the expected consumption rate, and whether the existing process is qualified for a solid, an aqueous product, or a solvent concentrate.

The reason to select a supplier should be supported by the actual technical response and agreed supply conditions. Clear identification, traceable documentation, and an appropriate specification provide a firmer basis for confidence than an unsupported claim that every available grade will perform identically.

Contact Ataman Kimya with the required quantity and your process constraints to discuss the offered 4-tert-Butylpyrocatechol specification. Reviewing those details together can help establish a suitable starting point for sampling, qualification, and procurement without separating the commercial decision from the chemistry that governs successful use.